OR • Patient with clinically suspected NAFLD as assessed by standard of care measures (risk factors for NAFLD, abnormal liver enzymes and/or fatty liver on imaging studies) who are scheduled to will undergo liver biopsy for the purpose of grading / staging the severity of their underlying liver disease